First Quarter 2018 Investor Presentation
Investor Presentation
First three months of 2018
Slide 83
Semaglutide demonstrated unprecedented weight loss in
phase 2 obesity trial
16.2% weight reduction with the highest
semaglutide dose in phase 2 obesity trial
Change in
body weight
(%)
-5
-10
-15
sema 0.05 mg
sema 0.2 mg
sema 0.4 mg
sema 0.1 mg
sema 0.3 mg
lira 3.0 mg
Placebo
16.2%
Key results and next steps
• Participants in the highest dose arms continued to lose
weight over the duration of the trial as the response curve
did not plateau in the highest dose arm
• Nearly two out of three patients experienced a weight loss of
10% or more with the highest dose of semaglutide
•
•
80% of patients completed the trial
Once-daily semaglutide had a well-tolerated safety profile,
with the most common adverse events being
gastrointestinal
Next steps: Phase 3 programme STEP and cardiovascular
outcomes study SELECT to be initiated in 2018
-20
0
8
12
16 20 28
36
44
52
Weeks
Note: All treatment arms are adjunct to diet and exercise
QD: Once-daily; sema: Semaglutide; lira: Liraglutide
changing
diabetes®
novo nordiskView entire presentation